WuXi XDC Cayman, Inc. 2268

WuXi XDC Cayman (SEHK:2268) reported GMP release for key production lines at its new Singapore site in 2026. The Singapore facility GMP release confirms the plant is cleared to produce clinical and commercial batches under regulatory quality standards. WuXi XDC Cayman and Ona Therapeutics agreed an exclusive global out-licensing collaboration that expands their existing partnership. The GMP release in Singapore and the expanded Ona Therapeutics out-licensing deal both need weighing against...

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today held a grand GMP release ceremony for its Singapore manufacturing site at Tuas Biomedical Park. From announcing the new site in March 2024 to achieving GMP release of the BCM3 antibody intermediate and conjugated drug substance dual-function production line and the DP4 facility in August 2026, this important mil

The deal grants Ona Therapeutics rights to develop an ADC targeting a single undisclosed target.

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced an out-licensing collaboration with Ona Therapeutics on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform. Ona Therapeutics is a global biotechnology company pioneering first-in-class ADCs to address treatment-resistant cancers.

WuXi XDC Cayman Inc (STU:L74) reports 37% revenue growth and a record service backlog of nearly $2 billion, while navigating margin pressures from new investments.

WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2026 ("Reporting Period").

WuXi XDC Cayman Inc. (the "WuXi XDC" or the "Group", stock code: 2268.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its interim results for the six months ended June 30, 2026 (the "Reporting Period").

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its BCM3 dual-function production line for antibody intermediates and drug substances of bioconjugates at Singapore site has successfully achieved GMP release. This milestone marks a new phase in the company's global capacity expansion, empowering clients worldwide to accelerate commercial manufac

NZS shifts capital toward AI infrastructure and healthcare leaders

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facility will be the Company's key DP facility designed to meet the latest and most stringent requirements for international markets, with expected output of approximately 100 million units of pre-filled syringes and vials per year.

WuXi XDC and BioDlink jointly hosted the 2026 Open Day under the theme "Stronger Together, Shaping the Future," bringing together biotech customers and industry experts for the first landmark event since BioDlink became a controlled subsidiary of WuXi XDC. The event showcased the combined strengths of the two organizations and their shared vision of building a globally competitive, integrated ADC/XDC CRDMO platform.

Global markets have recently experienced significant movements, with major U.S. stock indexes reaching record highs amid a backdrop of positive economic data and strong performances in AI-linked stocks, despite ongoing geopolitical tensions. In this environment, identifying undervalued stocks can be crucial for investors seeking opportunities that may not yet reflect their full potential value; such stocks often exhibit solid fundamentals or growth prospects that are temporarily overlooked by...

As global markets rally on the back of positive developments in the Middle East and encouraging economic data, investors are increasingly optimistic about future growth prospects. In such an environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for those looking to capitalize on market inefficiencies.

As global markets respond to geopolitical developments and economic data, Asian equities have shown resilience, with indices in Japan and China experiencing gains amid cautious optimism. In this environment, identifying undervalued stocks becomes crucial as investors seek opportunities that may offer potential value relative to current market conditions.

The Asian stock markets have recently experienced a rebound, supported by stronger-than-expected economic data from China and optimism around geopolitical de-escalation in the Middle East. As investors navigate these shifting conditions, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for growth in an otherwise cautious market environment.

As Asian markets navigate the complexities of geopolitical developments and economic data, investors are increasingly focused on identifying opportunities that may be undervalued by the broader market. In such an environment, a good stock is often characterized by strong fundamentals and resilience to external pressures, making it well-positioned to capitalize on potential market shifts.

As Asian markets navigate the complexities of geopolitical developments and economic data, investors are increasingly focused on identifying opportunities that may be undervalued amidst the broader market movements. In this context, a good stock is often characterized by its potential to trade below intrinsic value, presenting opportunities for growth as market conditions stabilize and investor sentiment improves.

As global markets show signs of optimism with de-escalating tensions in the Middle East and positive economic indicators, Asian stocks are also experiencing a modest rebound. In this environment, identifying undervalued stocks can be crucial as investors look for opportunities that may offer growth potential at attractive valuations.

As geopolitical tensions in the Middle East show signs of easing, Asian markets are experiencing a cautious rebound, buoyed by optimism around diplomatic progress and solid economic data from China. In this environment, identifying undervalued stocks becomes essential for investors seeking opportunities amid fluctuating market sentiment.